Previous Article | Next Article 
Infection and Immunity, December 2001, p. 7642-7651, Vol. 69, No. 12
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.12.7642-7651.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Phase Variation among Major Surface Antigens of
Mycoplasma penetrans
Kerstin
Röske,1
Alain
Blanchard,2
Isabelle
Chambaud,3
Christine
Citti,4
Jürgen H.
Helbig,1
Marie-Christine
Prevost,3
Renate
Rosengarten,4 and
Enno
Jacobs1,*
Institut für Medizinische Mikrobiologie
und Hygiene, Universitätsklinikum Carl Gustav Carus, Technische
Universität Dresden, D-01307 Dresden,
Germany1; INRA, Centre de Recherche de
Bordeaux, Institut de Biologie Végétale Moléculaire,
33883 Villenave D'Ornon Cedex,2 and
Unite d'Oncologie Virale, Institut Pasteur, 75724 Paris Cedex
15,3 France; and Institut für
Bakteriologie, Mykologie und Hygiene, Veterinärmedizinische
Universität Wien, 1210 Vienna,
Austria4
Received 30 May 2001/Returned for modification 10 July
2001/Accepted 24 August 2001
 |
ABSTRACT |
The pathogenicity and prevalence of Mycoplasma
penetrans, a Mycoplasma species recently
isolated from humans, are still debated. A major P35 antigen, which is
used as target epitope in serological assays, was shown to be a
phase-variable lipid-associated membrane protein (LAMP). In this study,
we performed a comparative analysis of the LAMP patterns from five
M. penetrans clinical isolates and from the type strain.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis profiles and
immunoblots with sera serially collected from an M.
penetrans-infected patient indicated that these strains
expressed different LAMP repertoires. Furthermore, the intraclonal
variation in the expression of LAMPs (P34A, P34B, P35, and P38) was
monitored by immunoblot analysis with three specific monoclonal
antibodies (MAbs) developed in this study and MAb 7 to P35. The phase
variation of these LAMPs occurs in an independent manner, with
frequencies of variation ranging from 10
2 to
10
4 per cell per generation. Consistent with their
amphipathic nature, the P34B and P38 antigens were found exposed at the
cell surface. The DNA sequence encoding the P38 antigen was defined and
found to be related to those of the P35 gene and other putative
LAMP-encoding genes, suggesting that these variable antigens are
encoded by a family of related genes. Finally, the serum samples from
an M. penetrans-infected patient contained antibodies
that reacted with a P36 antigen expressed in different M.
penetrans strains but not in the isolate recovered from this
patient. This result suggested that in vivo phase variation of P36
occurred, which would support a role for these LAMP variations in
avoiding the host's immune vigilance.
 |
INTRODUCTION |
Members of the genus
Mycoplasma have several characteristic features, including
small genome size in comparison to most other prokaryotes (10,
16, 17). The drastic reduction in their genome size during
evolution was only possible by the adoption of a parasitic lifestyle,
allowing these bacteria to acquire many nutrients from their hosts. As
obligatory parasites, they were also forced to develop efficient
strategies to avoid their host's immune surveillance. A number of
studies have demonstrated that mycoplasmas which colonize animals and
humans are able to change their surface antigen profile at high
frequency (for reviews, see references 5, 8,
and 35). Such antigenic variation is proposed to play a
key role in the evasion from the host immune response, a notion that
has received some support from in vitro experiments in which phase and
size variation of Mycoplasma hyorhinis surface antigens
provided protection from growth inhibition by polyclonal serum
(7). A second characteristic feature of mycoplasmas is the
absence of a cell wall or outer membrane. Consequently, the mycoplasma
surface lacks lipopolysaccharide and peptidoglycan. The major
variable antigens at the mycoplasma cell surface are lipoproteins,
which are also the dominant immunogens during mycoplasmal infections.
The mechanisms underlying the variation of these lipoproteins are
diverse and have been deciphered only for a limited number of
mycoplasma species (for a review, see references 8 and
28).
Mycoplasma penetrans was initially isolated from a urine
sample collected from a human immunodeficiency virus type 1 (HIV-1)-infected patient (22). This mycoplasma grows
fastidiously, and so far only a few isolates have been obtained from
clinical samples. M. penetrans has an elongated flask shape
morphology with a tip-like structure (21) that is
predicted to allow the mycoplasma to adhere and invade host cells
(12, 23). Epidemiological studies indicated an association
between M. penetrans and HIV infection (13, 33,
34), suggesting that M. penetrans could act as a
cofactor in the progression of the HIV-associated disease
(2). Indeed, Grau et al. (14) described an
association between active M. penetrans infections and an
accelerated progression of disease among HIV-infected patients.
However, it is not proven whether M. penetrans was the true
cause of the accelerated disease or only persisted in patients who were
particularly immunocompromised (14). There is a single
report describing the isolation of this mycoplasma from a patient who
was not coinfected with HIV. In this clinical case, the M. penetrans infection was associated with a primary antiphospholipid
syndrome (36), but no other study has since substantiated
this finding.
There is clearly a need to better understand the potential role of
M. penetrans infection in human disease. The epidemiological studies performed thus far are based on an M. penetrans-specific serological assay (13, 33). In
this assay, the diagnostic target molecules were lipid-associated
membrane proteins (LAMPs) which were extracted by using the neutral
detergent Triton X-114 (TX-114). The LAMPs from the type strain
M. penetrans GTU showed in immunoblots two major antigenic
proteins, P35 and P38, and less-abundant 61- and 103-kDa polypeptides
(33). The P35 protein was shown to be a surface-exposed
variable lipoprotein undergoing high-frequency phase variation
(9, 26, 27). These studies were performed by using the
M. penetrans type strain and the heterogeneity of LAMPs
between strains was not evaluated.
In the present study, we investigated the heterogeneity of LAMPs
between different M. penetrans clinical isolates and among their isogenic progenies. For this purpose, serial sera from an HIV-M. penetrans-coinfected patient were used together with
four newly developed monoclonal antibodies (MAbs) with unique LAMP specificities. These immunological tools allowed us to demonstrate that, in addition to P35, other putative lipoproteins, including P34B
and the sequenced P38, vary among isogenic variants in an independent manner.
 |
MATERIALS AND METHODS |
Mycoplasma culture condition.
M.
penetrans isolate ARA was kindly provided by Christiane Bebear
(University Victor Segalen, Bordeaux, France), and isolates HF-1, HF-2,
and HF-3 were as described elsewhere (36). M. penetrans 75 was isolated from the urine sediment of an
HIV-infected patient (Freiburg, Germany) as previously described
(18). The type strain GTU was kindly provided by S. Lo
(Armed Forces Institute of Pathology, Bethesda, Md.). Mycoplasmas were
grown at 37°C in liquid PPLO broth or PPLO agar (Difco, Detroit,
Mich.) supplemented with 20% heat-inactivated horse serum and 10%
yeast extract (15).
MAbs.
In order to establish specific MAbs to M. penetrans LAMP, BALB/c mice were immunized by the method of
Cianfriglia et al. (6) with 108
cells of M. penetrans 75 per immunization. The splenocytes
were fused with myeloma cells as previously described
(20). Hybridomas were grown in 24-well microtiter plates
in RPMI 1640 medium (Biochrom KG, Berlin, Germany) supplemented
with 15% fetal calf serum, 5 µl of 2-mercaptoethanol (Gibco-BRL,
Life Technologies, Karlsruhe, Germany)/liter, 20,000 IE of
penicillin/liter, and 20 mg of streptomycin (Gibco-BRL)/liter. After 10 days the hybridoma supernatants were tested for M. penetrans-specific MAbs in Western immunoblots. Antibody-producing
cells reacting with M. penetrans LAMPs were cloned by
dilution with hybridoma medium supplemented with 2% hypoxanthine-aminopterin-thymidine medium supplement (Sigma Chemical Co., St. Louis, Mo.). This procedure was repeated twice with in-between monitoring of antibody production by Western blot analysis as described
below. MAbs were also tested for their reactivity in colony immunoblots
of M. penetrans 75. By using this approach, three MAbs (MAb
C5 of immunoglobulin G2b [IgG2b] isotype, MAb D10 of IgG1 isotype,
and MAb G9 of IgG3 isotype) were selected. MAb 7 of IgG1 isotype, which
was previously shown to react with the P35 protein of M. penetrans GTU (26), was also used in this study. MAb
14, which reacts with the IMP14 peptide, is described below.
Electron microscopy.
Localization of the MAb target epitope
at the surface of M. penetrans was examined by using the
immunogold labeling technique described by Neyrolles et al.
(26). Briefly, M. penetrans cells were washed
once in 25 mM HEPES (Sigma) and resuspended in phosphate-buffered saline (PBS). Nickel grids were laid onto a droplet of a M. penetrans cell suspension for 20 min and fixed with 1%
paraformaldehyde at room temperature for 3 min. The grids were
incubated in PBS for 10 min and then with a PBS solution containing 50 µg of MAbs G9 or D10/ml for 1 h at room temperature. After five
washings in a solution containing PBS-0.5% bovine serum
albumin-0.1% gelatin, the grids were incubated for 1 h at room
temperature with an anti-mouse IgG and IgM antibody labeled with 10-nm
gold particles (Amersham) diluted 1:25 in PBS. The grids were washed
once in PBS and five times in water and then examined with a JEOL EX
1200 electron microscope at an accelerating voltage of 80 kV.
SDS-PAGE and Western immunoblotting.
Mycoplasma cells from a
broth culture were collected by centrifugation for 20 min at 5,400 × g and washed twice in PBS. M. penetrans membrane-associated proteins were fractionated by using
TX-114 (3) (Serva, Heidelberg,Germany) as previously described (31) with slight modifications. Briefly,
mycoplasmas from 50-ml cultures were resuspended in 1 ml of PBS
containing 2% (vol/vol) TX-114 and incubated for 2 h at 4°C
with shaking. After centrifugation at 4°C for 10 min at 13,000 × g, the supernatant containing the solubilized proteins
was subjected to three cycles of phase fractionation, including
incubation for micelle formation at 37°C for 5 min, followed by a
centrifugation step (13,000 × g, 3 min, room
temperature) for phase separation, resulting in an upper aqueous and a
lower detergent TX-114 phase. After collection of the detergent phase,
the concentration of TX-114 was readjusted with PBS to 2% and
incubated on ice for 10 min. This procedure was repeated twice. Prior
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
analysis, proteins that partitioned into the TX-114 detergent phase
were concentrated by ethanol precipitation (80% [vol/vol]). SDS-PAGE
was performed according to the method of Laemmli (19).
After electrophoresis, the proteins were stained with Coomassie blue or
transferred to nitrocellulose membrane (Protran BA83; Schleicher & Schuell, Dassel, Germany) by semidry electroblotting in a Multiphor II
electrophoresis unit (LKB Bromma). Membranes were blocked with
PBS-0.1% (vol/vol) Tween 20 (Serva) containing 10% fetal calf serum.
The immunostaining was performed by using the hybridoma supernatants of
MAb 7, MAb C5, MAb D10, MAb G9, or human sera as the primary antibody
and peroxidase-conjugated anti-mouse immunoglobulin (Dako A/S,
Glostrup, Denmark) or anti-human immunoglobulin (Sigma) as secondary antibody.
Colony immunoblotting and isolation of clonal variants derived
from M. penetrans
Colony immunoblotting was
performed as previously described (31), except that
4-chloro-1-naphthol was used as the peroxidase substrate. Colonies that
did not bind the MAbs were stained with Ponceau S. To establish a
clonal lineage, MAb-positive or -negative colonies were selected after
colony immunoblotting, propagated in 1 ml of culture and, after further
Western blot or colony blot analyses, were used to generate isogenic
progeny that exhibited alternative surface phenotypes. The frequency of
a particular epitope to undergo phase variation was assessed by colony
immunoblotting by calculating the number of colonies derived from a
single variant that had switched ON or OFF the expression of the epitope.
Expression of the putative lipoprotein pepIMP14 in
Escherichia coli.
The IMP14 gene sequence
(GenBank-EMBL accession no. AJ006697) described by Neyrolles et al.
(26) contained an open reading frame (ORF) encoding the
putative lipoprotein pepIMP14. The sequence between nucleotides 49 and
1069 of the IMP14 ORF was amplified by using a forward primer,
5'-TACGGGATCCTCTTCTTGTTCTTCAAC-3', located in
the conserved 5'-terminal coding region and a reverse primer,
5'-AATTGTCCCGGGCATCAAATGAAACATCTTTGCTTCTCTAG-3'.
The restriction sites for BamHI and XmaI
(underlined nucleotides) were engineered for further directional
cloning of the PCR fragment. First, the PCR product was directly
inserted into the pCR2.1-TOPO vector (Invitrogen, Groningen, The
Netherlands), and the four TGA triplets that code for tryptophan in
mycoplasmas were mutated to TGG codons for expression in E. coli as described in the QuickChange Site-Directed Mutagenesis Kit
(Stratagene, Heidelberg, Germany). The mutated insert was then digested
with BamHI and XmaI and ligated into the pQE30
vector (Qiagen, Hilden, Germany) cut with the same enzymes, and the
resulting ligation mixture was transformed into E. coli M15 (Qiagen).
A recombinant plasmid containing the pepIMP14 ORF in the correct
orientation was selected, and its sequence was verified by DNA
sequencing. The clone harboring the selected recombinant plasmid was
used to produce the IMP14 polypeptide fused at the N terminus with a
His6 tag to facilitate its purification by using
nickel-nitrilotriacetic acid (NTA) chromatography (Qiagen). The
purified IMP14 recombinant product was then used to produce the MAb
designated MAb 14 (IgM) according to the procedure described above.
Each immunization was performed with 100 µg of the purified
recombinant product.
Peptide sequencing.
Proteins of M. penetrans 75 that partitioned into the TX-114 detergent phase were separated by
electrophoresis and transferred to an Immobilon-P membrane (Schleicher
& Schuell). Proteins were detected by staining with Coomassie blue
R-250 (Ferak, Berlin, Germany), and the bands of interest were excised.
In collaboration with P. Rücknagel (Max Planck Institute, Halle,
Germany), proteins were digested with endoprotease Lys C (0.15 µg/20
µl of 25 mM Tris [pH 8.5]; Boehringer). The supernatants were
separated, and the membranes were extracted twice with 20 µl of 50%
formic acid in acetonitrile. The supernatant and extracts were
concentrated to 20 µl under nitrogen. The peptides were separated by
reversed-phase high-pressure liquid chromatography on a Shimadzu LC10
unit with an ET 125-by-2-mm Nucleosil 500-5 C3PPN column
(Macherey-Nagel) and linear gradient elution (eluent A, 0.09%
trifluoroacetic acid in water; eluent B, 0.08% trifluoroacetic
acid in acetonitrile; gradient, 1 to 40% B in 60 min; flow rate, 200 µl min
1; column temperature, 40°C).
Peptide-containing fractions were collected manually. Aliquots of the
fractions were used for MALDI-mass spectrometry and Edman sequencing
with an Applied Biosystems 476A Sequencer according to the
manufacturer's instructions.
DNA extraction, Southern blot analysis and cloning.
Genomic
DNA of M. penetrans 75 was extracted by conventional
procedures (24). For Southern blot analysis, 10 µg of
DNA was digested with the appropriate restriction enzyme and subjected to agarose gel electrophoresis, and the DNA fragments were transferred to Hybond-N+ membranes (Amersham International, plc.). Southern blot
hybridization was performed as previously described (26). Briefly, the membranes were prehybridized with hybridization solution containing 6× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium
citrate), 5× Denhardt solution, 0.1% SDS, and 100 µg of salmon
sperm DNA ml
1 for 2 h and incubated
overnight in hybridization solution with 32P-labeled oligonucleotide probes. The probes
were labeled by end labeling with T4 polynucleotide kinase. The
membranes were then washed twice with 6× SSC-0.1% SDS for 20 min at
room temperature. The oligonucleotide probes used in this study were
based on the peptide sequences derived from the fragments of the 38-kDa
protein and were as follows : P38-1,
5'-TTATAWATWCCWAAWGCWGC-3'; P38-2, 5'-TTWATATCTTCWSWWATWAATTCATT-3'; and P38-3,
5'-CATAWGGWGCWGCATCWACWACWACWGTATAWAC-3'. Since tryptophan
is preferentially coded in mycoplasmas by the codon TGA rather than
TGG, this triplet was used to design the oligonucleotides even though
it corresponds to a stop condon in the universal genetic code.
A PstI-DNA fragment of 3.5 kb hybridized with more than one
probe (P38-1 and P38-3 of the probes described above). This DNA fragment was excised from the agarose gel and purified by
electroelution (32). The eluted fragments were then
ligated with PstI-pUC18 vector, and the ligation mixture was
used to transform E. coli XL1-Blue competent cells.
Identification the recombinant plasmid of interest was performed by
Southern blot hybridization and was designated MP24.
For the expression of a recombinant P38 protein, a strategy similar to
that adopted for pepIMP14 expression was used, except that P38-specific
primer sequences allowed the amplification of the P38-encoding gene and
the mutagenesis of TGA triplets into TGG triplets. The forward primer
5'-TACGGGATCCTCTTCTTGTTCTTCTTACTGATAATGG-3' and
the reverse primer
5'-ATTG TCCCGGGAT TCACAG T TAAAC TAACATCAAAAGAAAAC TC-3'
used for amplification included the restriction sites for BamHI and XmaI (underlined nucleotides) for
cloning of the PCR fragment into the expression vector pQE30 (Qiagen).
RAPD analysis.
DNA of M. penetrans strains were
isolated with a QIAamp DNA Mini kit (Qiagen) according to the
manufacturer's instructions. The DNA concentration was determined
spectrometrically. Randomly amplified polymorphic DNA (RAPD) analysis
was performed as described by Geary et al. (11) and Marois
et al. (25), with slight modifications. Briefly, the PCR
mixture with a total reaction volume of 50 µl consists of
Taq polymerase buffer (Perkin-Elmer); a final concentration of 3 mM MgCl2; 250 µM concentrations each of
dATP, dTTP, dCTP, and dGTP (Hybaid AGS, Heidelberg, Germany); 2.5 U of
AmpliTaq Gold DNA polymerase (Perkin-Elmer); 300 ng of primer (primer
1281 [5'-AACGCGCAAC-3'] and/or primer 1254 [5'-CCGCAGCCAA-3']); and 40 ng of DNA. The PCR was
performed in a Perkin-Elmer GenAmp PCR System 9600. The following
reaction conditions were used: 1 cycle of 97°C for 5 min; 4 cycles at
94°C for 5 min, 36°C for 5 min, and 72°C for 5 min; followed by
31 cycles of 94°C for 1 min, 36°C for 1 min, and 72°C for 1 min;
and terminated by 1 cycle of 72°C for 10 min. The amplified products
(15 µl) were electrophoresed in 1,5% agarose gels in TBE (10.8 g of
Tris-HCl liter
1, 5.5 g of borate
liter
1, 0.74 g of
Na2EDTA liter
1) for
1 h at 0.15 A. Then, 5 µl of Smart Ladder (Eurogentec) was run
in each gel as the molecular size standard. The gels were stained with
ethidium bromide and visualized by UV transillumination.
Nucleotide sequencing and sequence analysis.
The DNA insert
of the recombinant plasmid MP24 was sequenced by using BigDye
Terminator RR Mix (PE Applied Biosystems) and an automated sequencer
(ABI Prism 377 DNA Sequencer, Perkin-Elmer). Sequence data were
analyzed by using the software programs provided by the sequencer and
by using the GenBank and EMBL databases. Published sequences P35 and
P30 (L38250) and IMP14 (AJ006699) were obtained from GenBank-EMBL. The
GenBank-EMBL accession number of the DNA sequence encoding P38 is
AF260642.
 |
RESULTS |
Analysis of putative LAMPs of different M. penetrans
isolates.
In the present study, LAMP profiles of uncloned M. penetrans isolates that had originally been cultured from (i) the
urine sediment of an AIDS patient in Germany (isolate 75), (ii) the urine sediment of an HIV-infected patient in France (isolate ARA), and
(iii) the blood (HF-1), the tracheal aspirate (HF-2), and the throat
(HF-3) of an HIV-negative patient with primary antiphospholipid syndrome (36) were analyzed by SDS-PAGE and Western
blotting (Fig. 1 and
2).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
LAMP profile heterogeneity between M.
penetrans isolates. TX-114 extraction of different M.
penetrans patient isolates showing the heterogeneity of LAMP
patterns. The results of SDS-PAGE of TX-114-fractionated LAMPs of
M. penetrans type strain GTU and patient isolates 75, ARA, HF-1, HF-2, and HF-3 stained with Coomassie blue and corresponding
immunoblots incubated with serum of patient 75 collected in either
February 1993 or March 1995 are shown.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Different expressions of LAMP profiles in several
M. penetrans patient isolates (75, ARA, HF-1, HF-2, and
HF-3) and the type strain GTU determined by using Coomassie blue
staining and immunostaining with MAbs D10, G9, 7, 14, or C5. MAb D10
reacted with a 34-kDa molecule (P34B). MAb G9 recognized a 38-kDa
molecule (P38) in M. penetrans GTU and 75. MAb 7 stained
P35. MAb 14 recognized a 34-kDa molecule in M. penetrans
75, named P34A. MAb C5 reacted with a common epitope of LAMPs with
molecular masses ranging between 30 and 38 kDa.
|
|
The LAMP profiles were markedly different between the isolates,
although in each case Coomassie blue staining revealed that the most
abundant products migrated between 34 and 40 kDa, with products of 30, 62, 94, and 96 kDa only detectable when the sample load was increased.
All M. penetrans strain and isolates tested in this study
expressed a 35-kDa products which reacted with the MAb 7, an antibody
which recognizes the P35 antigen previously identified in the type
strain GTU (26). Other than this common P35 antigen, no
LAMP profiles were identical except for two (HF-1 and HF-3) isolates
obtained from different body sites of the same patient.
By using two sera collected at two different times from patient 75, the
humoral response to the M. penetrans LAMPs was monitored by
Western blot analyses. The first serum sample (collected in February
1993) contained antibodies that recognized LAMPs of 34, 35, and 38 kDa
expressed by the M. penetrans isolate recovered from this
patient (isolate 75). Beside the P35 shared antigen, immunoprofiles
observed with this serum differed among the other strain and isolates.
More specifically, this patient serum recognized a product of 38 kDa in
strain GTU and of 36 kDa in isolates HF-1 and HF-3. This later 36-kDa
reactivity was not detected in isolates ARA and HF-2.
The second serum sample from patient 75 was collected 2 years later at
the time of isolation of M. penetrans 75 in March 1995. This
serum showed a stronger reactivity with molecules of 34 to 38 kDa but
also recognized additional LAMPs of 62 and 94 kDa in M. penetrans isolate from patient 75. This serum sample also
recognized additional proteins in other isolates. The GTU profile
resembled that of isolate 75. In the LAMPs from isolates HF-2 and HF-3, additional faintly labeled bands were observed.
To further characterize the different LAMPs of isolate 75, MAbs to
M. penetrans 75 surface molecules were generated by using mycoplasma cells as antigen. Three MAbs were established based on their
specific reactivity in Western blot analysis and recognized the major
LAMPs. Western blot analysis revealed that the MAbs D10 and G9
specifically recognized a single, distinct product of 34 (P34B) and 38 (P38) kDa, respectively (Fig. 2). Only the type strain GTU and isolate
75 expressed the MAb G9-specific product. The third MAb, C5, strongly
reacted with LAMPs of 38, 36, 35, 34, and 30 kDa, suggesting that the
MAb C5-specific epitope is shared by multiple lipoproteins. MAb 14 (generated from a recombinant pepIMP14 antigen [26])
recognized a 34-kDa molecule similar to that stained by MAb D10.
However, MAb 14 and MAb D10 recognized distinct molecules, since
reactivity of MAb 14 was found only with isolate 75, while MAb D10
reacted with the type strain and all of the isolates except ARA. As a
control, the MAb 7 (26) was also included in this
analysis, and the results demonstrated that P35 is expressed in all of
the isolates analyzed, confirming that the common 35-kDa band was
indeed P35 (Fig. 2).
Typing of M. penetrans isolates with RAPD.
RAPD
patterns generated with primer 1281 alone showed a limited banding,
whereas the amplification with primer 1254 or the combination of both
primers according to the method of Marois et al. (25)
resulted in a more complex RAPD banding pattern. The RAPD patterns of
M. penetrans strain GTU and isolates ARA, HF-1, HF-2, and
HF-3 generated with primer 1254 were identical with slight differences
in the intensity (Fig. 3), but isolate 75 showed an additional band of 1.3 kb and two lacking bands of 0.75 and
0.8 kb. Comparison of the RAPD patterns generated with the combination
of primers 1254 and 1281 M. penetrans GTU showed no 1.4- and
0.9-kb fragments. M. penetrans 75 showed an additional amplification product of 1.3 kb. The overall banding patterns of
isolates HF-1, HF-2, and HF-3 and ARA showed identical patterns with
the amplification protocols but were distinguishable from those of
strain GTU and isolate 75.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 3.
RAPD patterns of M. penetrans strain GTU
and isolates 75, ARA, HF-1, HF-2, and HF-3 after amplification with
primer 1281, 1254 or a combination of both primers. DNA basepair size
standards are shown on the left and on the right.
|
|
P34B and P38 undergo antigenic variation in
vitro
Immunostaining of M.
penetrans 75 colonies with MAbs D10 and G9 revealed a pattern
composed of positive, negative and sectored colonies (Fig.
4B), indicating that the corresponding
target epitopes are surface exposed and may undergo variation in
expression.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 4.
Western and colony immunoblots of clonal variants
derived from M. penetrans isolate 75 showing
phase-variable expression of P34B and P38. (A) SDS-PAGE analysis of
LAMPs from two selected clones of M. penetrans 75. Clone
K1 was positive with P38 (MAb G9) and negative with MAb D10, and clone
2 reacted positively with MAb D10 (P34B) and negatively with MAb G9.
(B) Clones K1 and K2 were grown on agar plates, and colony immunoblots
were labeled with MAb D10 or MAb G9. Staining of clone K1 colonies with
MAb D10 revealed the presence of colonies among the P34B negative
population that have reverted to the P34B-positive phenotype (arrow p).
Colonies generated with clone K2 are predominantly positive for P34B,
though a few present a negative (arrow n) and sectoring (arrow s)
staining. Staining of colonies generated with clone K1 with MAb G9
showed predominantly the P38-positive phenotype. Colonies of clone K2
were negative. Bar, 100 µm.
|
|
To assess phase variation of D10 and of G9 target epitopes, cloned D10-
and G9-positive or -negative variants from M. penetrans 75 were selected and tested by colony and Western immunoblotting (Fig. 4).
Results obtained with clones K1 and K2 revealed that expression of P38
is only detected in clone K1 (G9 positive and D10 negative in colony
immunoblotting), while P34B was expressed in its sibling, K2 (D10
positive and G9 negative in colony immunoblotting). Variations in
expression of P34B and P38 occurred with high frequency in propagating
populations, resulting in the appearance of minor populations that
presented a different phenotype (Fig. 4B, for clone K1 and K2). The
variation rate of P34B and P38 differed. It was estimated by colony
immunoblotting to be 10
2 per cell per
generation for P34B and 10
4 per cell per
generation for P38.
To investigate independent ON-OFF switches of P34A, P34B, P35, and P38,
clonal lineages of M. penetrans 75 were established. When
these progeny were analyzed, the results showed that isogenic variants
of the M. penetrans 75 clonal lineage differed in their expression profiles (Fig. 5). M. penetrans 75 expressed P34A, P34B, P35, and P38 (Fig. 5, lane 1),
while subclones showed a change in the expression of P34B and P38 from
OFF to ON (P34B, lane 5
6; P38, lane 3
4) and vice versa (P34B,
lane 3
5; P38, lane 4
7). Only a switch from ON to OFF was observed
for P34A, and it is not yet known whether reversion from OFF to ON can
occur. Colony immunoblotting could not be used as a method to screen for P34A phase variants since the only available P34A-specific MAb does
not recognize a surface-accessible epitope. P35 was constantly detected, with one clonal variant (lane 8) showing a weak
immunoreaction with P35 and no 35-kDa band by Coomassie blue staining.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
Immunoblots of TX-114-extracted LAMPs of a clonal
lineage of M. penetrans 75 incubated with MAb 7, G9,
D10, or 14. Lane 1 represents M. penetrans 75, and
descendants are shown in lanes 2 to 8. The pedigree of the descendants
is indicated by the arrows. The clonal lineage shows variability in
protein expression of P34B from ON to OFF (lane 3 to lane 5) and vice
versa (lane 5 to lane 6) and revealed ON and OFF switching of P38 (lane
3 [OFF] to lane 4 [ON] lane 7 [OFF]).
|
|
Surface exposure of M. penetrans P34B and P38.
The cell surface exposure of P34B and P38 was further assessed by
immunoelectron microscopy of M. penetrans GTU and 75 with specific MAbs D10 and G9 and gold-labeled secondary antibodies (Fig.
6). The MAbs D10 (Fig. 6A) and G9 (Fig.
6C and D) target epitopes were evenly distributed over the mycoplasma
cell surfaces. Additionally, M. penetrans GTU and 75 cultures showed cells with bound P34B- and P38-specific MAbs; however,
both cultures also contained cells without labeled surfaces.

View larger version (94K):
[in this window]
[in a new window]
|
FIG. 6.
Variable surface expression of P34B and P38 of M.
penetrans cells by immunogold labeling electron microscopy.
P34B-positive (A) and P34B-negative (B) mycoplasmas were examined in
one culture of M. penetrans GTU. Cells of isolate 75 (C)
and M. penetrans GTU (D) were labeled with MAb G9.
Differences in the quantity of MAb binding sites at the cell surface
are shown for MAbs D10 (A) and G9 (C and D). Bar, 200 nm.
|
|
Sequence analysis of the P38 coding sequence.
Amino acid
sequencing of peptides derived from enzymatic digestion of the isolated
38-kDa protein led to the generation of three peptide sequences: p381
(ISAALGIYN), p382 (TTNELISEDIK), and p383
(VYTVVVDAAPYDSNYVWDDGSTDTK). Southern blots of digested genomic DNA of M. penetrans 75 were hybridized with three
specific oligonucleotide probes corresponding to each sequenced
peptide. Southern blot analysis revealed that a 3.5-kb PstI
DNA fragment bound the two oligonucleotide probes corresponding to p381
and p383, while no hybridization signal was obtained with the third probe (data not shown). Cloning and sequencing of this 3.5-kb PstI DNA fragment revealed the presence of a 500-bp region
containing a partial ORF that included the peptide sequences p381 and
p383. A stop codon was found 11 amino acids downstream of the region encoding p383, indicating that the 500 bp localized on the 3.5-kb DNA
fragment encodes the P38 C-terminal region. The deduced P38 sequence
present DNA homologies with the translation products of several
recently described genes (designated mpl for M. penetrans lipoprotein [26]): P35, P30, P34A
(pepIMP14), pep1IMP12, and pepIMP13. One feature of these genes
is that they possess identical sequences encoding for the signal
peptide at the N terminus. Therefore, a forward primer
(5'-CAGTTCCAGTAATTGTTTCTTC-3') corresponding to the
conserved N-terminal region and a reverse primer
(5'-TTATATCTATGAAAAGGAAATGTA-3') located at the 3' end of
the identified ORF were used for the amplification of the entire P38
gene. An amplification product of 1 kb was obtained and sequenced. The
translated amino acid sequence encoded by this 1-kb DNA fragment
contained, in addition to p381 and p383, the third p382 peptide
sequence. The molecular mass for the mature lipoprotein deduced from
the DNA sequence was 37 kDa. Further analysis (Fig.
7) revealed that P38 exhibits a high
degree of sequence similarity with other members of the mpl
family of LAMPs (26). Among this family, P34A had the
greatest identity (36.4% identity) to P38. P38 had no homology to any
other protein recorded in the databases. The genes encoding P30, P35, and P34A are known to be clustered in the M. penetrans
genome (26). The relative location of the P38 gene to this
cluster has not been ascertained, although a putative lipoprotein gene is also present downstream of the P38 gene, within the cloned DNA
fragment. Although analysis of this lipoprotein gene is incomplete, the
preliminary data suggest that it is new member of the mpl family.

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 7.
Alignment of P38 deduced amino acid sequence with that
of the previously identified P30, P35, and P34A (pepIMP14) of M.
penetrans by using the DNAstar software. Boxed letters
represent amino acids that are common to three of the four sequences.
|
|
Recombinant fusion proteins representing P38 and P34A (pepIMP14) were
expressed in E. coli and, as expected, MAb G9 recognized the
recombinant protein P38. The recombinant forms of both P38 and P34A
were recognized by MAb C5. Since both of the recombinant proteins lack
a signal peptide required for their lipid modification in E. coli, this result indicates that the epitope recognized by MAb C5
is encoded by both genes and is proteinaceous in character.
 |
DISCUSSION |
Comparative analysis of the LAMP profiles of the few available
clinical isolates of M. penetrans indicated that this
species possesses a complex family of related but distinct variable
surface lipoproteins and that these lipoproteins showed a high degree of heterogeneity in their expression. Interestingly, our analysis also
revealed that M. penetrans HF isolated from two distinct body sites of the same patient, expressed different combinations of
LAMPs. A major 36-kDa band could be detected in the isolates HF-1 and
HF-3, respectively, but was lacking in the Coomassie blue staining of
isolate HF-2. In Western blot analysis, a faint 36-kDa band could be
detected also in HF-2 (Fig. 1, patient serum 03/1995) most likely
indicating that a minor population of HF-2 expressed the 36-kDa
protein. The three M. penetrans HF isolates presented an
identical banding pattern in RAPD analysis, supporting the hypothesis
that these isolates had the same genetic origin. This result suggested
either that mycoplasma populations presenting different LAMP phenotypes
coexisted at the same site within a single host, with a given variant
being selected during the isolation procedure, or that some of the
phenotypic variations correspond to an adaptation to specific
colonization sites. The ability of an M. penetrans
population to express different LAMP repertoires in a single colonized
host could also provide an explanation regarding the nature of the
humoral response observed in the patient 75. In patient 75, LAMPs
related to 34-, 35-, and 38-kDa molecules are highly immunogenic. This
patient developed also a strong humoral response against P36 even
though it was not detectable with Coomassie staining in the clinical
isolate 75. Here we were able to demonstrate by in vitro subcloning
that this isolate retained the genetic ability to revert in vitro to a
P36-positive phenotype as a major part of the LAMP pattern (Fig. 5).
Based on this result, it is more likely that P36 was expressed in vivo
at some point during the infection and represented a potent antigen
eliciting an immune response in patient 75. Altogether, these data
strongly support that phase variation of M. penetrans LAMPs
occurs in vivo.
Although the serum collected in 1993 from the HIV-positive patient 75 contained circulating antibodies that strongly bound to different
LAMPs, M. penetrans was isolated 2 years later, indicating that the strong humoral response was not sufficient to eradicate mycoplasmas from the urogenital tract. It is possible that the HIV-associated immunodeficiency of the patient was a factor
predisposing for the mycoplasma persistence. However, this observation
is also in accordance with data obtained by Cartner et al.
(4) showing that mice infected with the respiratory
pathogen Mycoplasma pulmonis develop an humoral response
against the mycoplasma that does not block the colonization of the
target tissue but rather plays a role in preventing the systemic
dissemination of the pathogen.
Phase variation of surface antigens was previously demonstrated for
M. penetrans type strain GTU, with a focus on the P35 antigen (26). By using newly established MAbs, we
documented that at least three further prominent lipoproteins (P34A,
P34B, and P38) can undergo phase variation in vitro. It could be
demonstrated with the different clonal variants of M. penetrans 75 that MAb D10, MAb G9, MAb 7, and MAb 14 reacted with
distinct LAMPs. The ON and OFF switching of P34B and P38 was
demonstrated with the clonal lineage. The switching frequency of P34B
of 10
2 per cell per generation is among the
highest rates of variation measured thus far for lipoproteins of animal
pathogenic mycoplasmas (29). The different combinations of
expressed LAMPs in the clonal variants revealed that variation of P34A,
P34B, P35, and P38 appeared to be independent of each other.
P38 is a new member of a family of related surface proteins in M. penetrans 75 that undergo intraclonal variation and that share a
common immunogenic region, as demonstrated by using the newly
established MAb C5.
The development of the MAb C5 is of particular interest because it
allows the detection of a spectrum of related surface antigens. The MAb
C5 epitope is linked to the protein moiety because the MAb C5
cross-reacts with the recombinant proteins P38 and P34A expressed in
E. coli in absence of their signal peptide required for the
lipid modification. Unlike a large number of other variable proteins
identified in other mycoplasmas (1, 30), mpl
genes do not contain repeated sequence which might be involved in size variation. Therefore, the ability of MAb C5 to detect the
TX-114-extracted proteins in the molecular mass range of 30 to 38 kDa
might help in future studies to monitor a distinct ON or OFF switched
status of each member of this family without establishing specific MAbs for each individual LAMP. Furthermore, this effective reagent together
with the other MAb developed in this study might be of relevance to
define which set of expressed molecules should be necessary to support
an in vivo colonization of the lower or even upper urogenital tract and
to define a changing surface pattern of M. penetrans in
later stages of a developing immune response.
Based on the finding that major components of M. penetrans
cells undergo phase variations, it is noteworthy to speculate that LAMP
diversity generated by the mycoplasma, despite a limited amount of
genetic information, may contribute to host adaptation as a pathogenic
mechanism and participate in establishing successful chronic infection
of the human host.
 |
ACKNOWLEDGMENTS |
We thank Tsuguo Sasaki (National Institute of Infectious
Diseases, Tokyo, Japan) for the gift of MAb 7. We thank P. Rücknagel for the sequencing of peptides. We also thank S. Ferris
and S. Gäbler for excellent technical assistance.
This work was supported by the Deutsche Forschungsgemeinschaft (Ja
399/8-1).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Medizinische Mikrobiologie und Hygiene,
Universitätsklinikum Carl Gustav Carus, Technische
Universität Dresden, Fetscherstrasse 72, D-01307 Dresden,
Germany. Phone: 49-351-4586550. Fax: 49-351-4586310. E-mail: address:
enno.jacobs{at}mailbox.tu-dresden.de.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Behrens, A.,
M. Heller,
H. Kirchhoff,
D. Yogev, and R. Rosengarten.
1994.
A family of phase- and size-variant membrane surface lipoprotein antigens (Vsps) of Mycoplasma bovis.
Infect. Immun.
62:5075-5084[Abstract/Free Full Text].
|
| 2.
|
Blanchard, A.,
L. Montagnier, and M. L. Gougeon.
1997.
Influence of microbial infections on the progression of HIV disease.
Trends Microbiol.
5:326-331[CrossRef][Medline].
|
| 3.
|
Bordier, C.
1981.
Phase separation of integral membrane proteins in Triton X-114 solution.
J. Biol. Chem.
256:1604-1607[Abstract/Free Full Text].
|
| 4.
|
Cartner, S. C.,
J. R. Lindsey,
J. Gibbs-Erwin,
G. H. Cassell, and J. W. Simecka.
1998.
Roles of innate and adaptive immunity in respiratory mycoplasmosis.
Infect. Immun.
66:3485-3491[Abstract/Free Full Text].
|
| 5.
|
Chambaud, I.,
H. Wroblewski, and A. Blanchard.
1999.
Interactions between mycoplasma lipoproteins and the host immune system.
Trends Microbiol.
7:493-499[CrossRef][Medline].
|
| 6.
|
Cianfriglia, M.,
D. Armellini,
A. Massone, and M. Mariani.
1983.
Simple immunization for high-frequency production of soluble antigen-specific hybridomas.
Hybridoma
2:451-457[Medline].
|
| 7.
|
Citti, C.,
M. F. Kim, and K. S. Wise.
1997.
Elongated versions of Vlp surface lipoproteins protect Mycoplasma hyorhinis escape variants from growth-inhibiting host antibodies.
Infect. Immun.
65:1773-1785[Abstract].
|
| 8.
|
Citti, C., and R. Rosengarten.
1997.
Mycoplasma genetic variation and its implication for pathogenesis.
Wien. Klin. Wochenschr.
109:562-568[Medline].
|
| 9.
|
Ferris, S.,
H. L. Watson,
O. Neyrolles,
L. Montagnier, and A. Blanchard.
1995.
Characterization of a major Mycoplasma penetrans lipoprotein and of its gene.
FEMS Microbiol. Lett.
130:313-319[CrossRef][Medline].
|
| 10.
|
Fraser, C. M.,
J. D. Gocayne,
O. White,
M. D. Adams,
R. A. Clayton,
R. D. Fleischmann,
C. J. Bult,
A. R. Kerlavage,
G. Sutton,
J. M. Kelley,
J. L. Fritchman,
J. F. Weidman,
K. V. Small,
M. Sandusky,
J. Fuhrman,
D. Nguyen,
T. R. Utterback,
D. M. Saudek,
C. A. Phillips,
J. M. Merrick,
J.-F. Tomb,
B. A. Dougherty,
K. F. Bott,
P.-C. Hu,
T. S. Lucier,
S. N. Petterson,
H. O. Smith,
C. A. Hutchison,
I. I. I., and J. C. Venter.
1995.
The minimal gene complement of Mycoplasma genitalium.
Science
270:397-403[Abstract/Free Full Text].
|
| 11.
|
Geary, S. J.,
M. H. Forsyth,
S. Aboul-Saoud,
G. Wang,
D. E. Berg, and C. M. Berg.
1994.
Mycoplasma gallisepticum strain differentiation by arbitrary primer PCR (RAPD) fingerprinting.
Mol. Cell. Probes
8:311-316[CrossRef][Medline].
|
| 12.
|
Giron, J. A.,
M. Lange, and J. B. Baseman.
1996.
Adherence, fibronectin binding, and induction of cytoskeleton reorganization in cultured human cells by Mycoplasma penetrans.
Infect. Immun.
64:197-208[Abstract].
|
| 13.
|
Grau, O.,
B. Slizewicz,
P. Tuppin,
V. Launay,
E. Bourgeois,
N. Sagot,
M. Moynier,
A. Lafeuillade,
H. Bachelez, and J. P. Clauvel.
1995.
Association of Mycoplasma penetrans with human immunodeficiency virus infection.
J. Infect. Dis.
172:672-681[Medline].
|
| 14.
|
Grau, O.,
P. Tuppin,
B. Slizewicz,
V. Launay,
C. Goujard,
E. Bahraoui,
J. F. Delfraissy, and L. Montagnier.
1998.
A longitudinal study of seroreactivity against Mycoplasma penetrans in HIV-infected homosexual men: association with disease progression.
AIDS Res. Hum. Retrov.
14:661-667[Medline].
|
| 15.
|
Hayflick, L.
1965.
Tissue cultures and mycoplasma.
Tex. Rep. Biol. Med.
23:285-303.
|
| 16.
|
Himmelreich, R.,
H. Hilbert,
H. Plagens,
E. Pirkl,
B. C. Li, and R. Herrmann.
1997.
Comparative analysis of the genomes of the bacteria Mycoplasma pneumoniae and Mycoplasma genitalium.
Nucleic Acids Res.
25:701-712[Abstract/Free Full Text].
|
| 17.
|
Himmelreich, R.,
H. Plagens,
H. Hilbert,
B. Reiner, and R. Herrmann.
1996.
Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae.
Nucleic Acids Res.
24:4420-4449[Abstract/Free Full Text].
|
| 18.
|
Klär, U., and E. Jacobs.
1996.
Mycoplasma penetrans und Mycoplasma fermentans: Nachweise im Urogenitaltrakt immunsupprimierter Wirte.
Klin. Labor
6:540.
|
| 19.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 20.
|
Lindl, T., and J. Bauer.
1989.
Zell und Gewebekultur.
Gustav Fischer Verlag, Stuttgart, Germany.
|
| 21.
|
Lo, S. C.,
M. M. Hayes,
R. Y. Wang,
P. F. Pierce,
H. Kotani, and J. W. Shih.
1991.
Newly discovered mycoplasma isolated from patients infected with HIV.
Lancet
338:1415-1418[CrossRef][Medline].
|
| 22.
|
Lo, S. C.,
M. M. Hayes,
J. G. Tully,
R. Y. Wang,
H. Kotani,
P. F. Pierce,
D. L. Rose, and J. W. Shih.
1992.
Mycoplasma penetrans sp. nov., from the urogenital tract of patients with AIDS.
Int. J. Syst. Bacteriol.
42:357-364[Abstract/Free Full Text].
|
| 23.
|
Lo, S. C.,
M. M. Hayes,
H. Kotani,
P. F. Pierce,
D. J. Wear,
P. B. Newton,
J. G. Tully, and J. W. Shih.
1993.
Adhesion onto and invasion into mammalian cells by Mycoplasma penetrans: a newly isolated mycoplasma from patients with AIDS.
Mod. Pathol.
6:276-280[Medline].
|
| 24.
|
Marmur, J.
1961.
A procedure for the isolation of deoxyribonucleic acid from microorganisms.
J. Mol. Biol.
3:208-218.
|
| 25.
|
Marois, C.,
F. Dufour-Gesbert, and I. Kempf.
2001.
Comparison of puls-field gel electrophoresis with random amplified polymorphic DNA for typing of Mycoplasma synoviae.
Vet. Microbiol.
79:1-9[CrossRef][Medline].
|
| 26.
|
Neyrolles, O.,
I. Chambaud,
S. Ferris,
M. C. Prevost,
T. Sasaki,
L. Montagnier, and A. Blanchard.
1999.
Phase variations of the Mycoplasma penetrans main surface lipoprotein increase antigenic diversity.
Infect. Immun.
67:1569-1578[Abstract/Free Full Text].
|
| 27.
|
Neyrolles, O.,
J. P. Eliane,
S. Ferris,
R. Ayr Florio da Cunha,
M. C. Prevost,
E. Bahraoui, and A. Blanchard.
1999.
Antigenic characterization and cytolocalization of P35, the major Mycoplasma penetrans antigen.
Microbiology
145:343-355[Medline].
|
| 28.
|
Razin, S.,
D. Yogev, and Y. Naot.
1998.
Molecular biology and pathogenicity of mycoplasmas.
Microbiol. Mol. Biol. Rev.
62:1094-1156[Abstract/Free Full Text].
|
| 29.
|
Rosengarten, R., and K. S. Wise.
1990.
Phenotypic switching in mycoplasmas: phase variation of diverse surface lipoproteins.
Science
247:315-318[Abstract/Free Full Text].
|
| 30.
|
Rosengarten, R., and K. S. Wise.
1991.
The Vlp system of Mycoplasma hyorhinis: combinatorial expression of distinct size variant lipoproteins generating high-frequency surface antigenic variation.
J. Bacteriol.
173:4782-4793[Abstract/Free Full Text].
|
| 31.
|
Rosengarten, R.,
A. Behrens,
A. Stetefeld,
M. Heller,
M. Ahrens,
K. Sachse,
D. Yogev, and H. Kirchhoff.
1994.
Antigen heterogeneity among isolates of Mycoplasma bovis is generated by high-frequency variation of diverse membrane surface proteins.
Infect. Immun.
62:5066-5074[Abstract/Free Full Text].
|
| 32.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 33.
|
Wang, R. Y.,
J. W. Shih,
T. Grandinetti,
P. F. Pierce,
M. M. Hayes,
D. J. Wear,
H. J. Alter, and S. C. Lo.
1992.
High frequency of antibodies to Mycoplasma penetrans in HIV-infected patients.
Lancet
340:1312-1316[CrossRef][Medline].
|
| 34.
|
Wang, R. Y.,
J. W. Shih,
S. H. Weiss,
T. Grandinetti,
P. F. Pierce,
M. Lange,
H. J. Alter,
D. J. Wear,
C. L. Davies, and R. K. Mayur.
1993.
Mycoplasma penetrans infection in male homosexuals with AIDS: high seroprevalence and association with Kaposi's sarcoma.
Clin. Infect. Dis.
17:724-729[Medline].
|
| 35.
|
Wise, K. S.,
D. Yogev, and R. Rosengarten.
1992.
Antigenic variation, p. 473-490.
In
J. Maniloff, R. N. McElhaney, L. R. Finch, and J. Baseman (ed.), Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, D.C.
|
| 36.
|
Yanez, A.,
L. Cedillo,
O. Neyrolles,
E. Alonso,
M. C. Prevost,
J. Rojas,
H. L. Watson,
A. Blanchard, and G. H. Cassell.
1999.
Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome.
Emerg. Infect. Dis.
5:164-167[Medline].
|
Infection and Immunity, December 2001, p. 7642-7651, Vol. 69, No. 12
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.12.7642-7651.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Gaurivaud, P., Persson, A., Grand, D. L., Westberg, J., Solsona, M., Johansson, K.-E., Poumarat, F.
(2004). Variability of a glucose phosphotransferase system permease in Mycoplasma mycoides subsp. mycoides Small Colony. Microbiology
150: 4009-4022
[Abstract]
[Full Text]
-
van der Woude, M. W., Baumler, A. J.
(2004). Phase and Antigenic Variation in Bacteria. Clin. Microbiol. Rev.
17: 581-611
[Abstract]
[Full Text]
-
Horino, A., Sasaki, Y., Sasaki, T., Kenri, T.
(2003). Multiple Promoter Inversions Generate Surface Antigenic Variation in Mycoplasma penetrans. J. Bacteriol.
185: 231-242
[Abstract]
[Full Text]
-
Sasaki, Y., Ishikawa, J., Yamashita, A., Oshima, K., Kenri, T., Furuya, K., Yoshino, C., Horino, A., Shiba, T., Sasaki, T., Hattori, M.
(2002). The complete genomic sequence of Mycoplasma penetrans, an intracellular bacterial pathogen in humans. Nucleic Acids Res
30: 5293-5300
[Abstract]
[Full Text]